BR112012000209A2 - processo para a produção de heterodímeros de ácido glutâmico - Google Patents

processo para a produção de heterodímeros de ácido glutâmico

Info

Publication number
BR112012000209A2
BR112012000209A2 BR112012000209A BR112012000209A BR112012000209A2 BR 112012000209 A2 BR112012000209 A2 BR 112012000209A2 BR 112012000209 A BR112012000209 A BR 112012000209A BR 112012000209 A BR112012000209 A BR 112012000209A BR 112012000209 A2 BR112012000209 A2 BR 112012000209A2
Authority
BR
Brazil
Prior art keywords
heterodimers
production
glutamic acid
glutamic
acid
Prior art date
Application number
BR112012000209A
Other languages
English (en)
Other versions
BR112012000209B1 (pt
BR112012000209B8 (pt
Inventor
zimmermann Craig
W Babich John
P Maresca Kevin
Original Assignee
Molecular Insight Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Insight Pharm Inc filed Critical Molecular Insight Pharm Inc
Publication of BR112012000209A2 publication Critical patent/BR112012000209A2/pt
Publication of BR112012000209B1 publication Critical patent/BR112012000209B1/pt
Publication of BR112012000209B8 publication Critical patent/BR112012000209B8/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0497Organic compounds conjugates with a carrier being an organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001Acyclic or carbocyclic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C273/00Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C273/18Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups of substituted ureas
    • C07C273/1854Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups of substituted ureas by reactions not involving the formation of the N-C(O)-N- moiety
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/36Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids
    • C07C303/40Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids by reactions not involving the formation of sulfonamide groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/22Tin compounds
    • C07F7/2208Compounds having tin linked only to carbon, hydrogen and/or halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112012000209A 2009-06-15 2010-06-15 heterodímeros de ácido glutâmico e seus processos de preparação BR112012000209B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18712009P 2009-06-15 2009-06-15
US61/187,120 2009-06-15
PCT/US2010/038645 WO2010147965A2 (en) 2009-06-15 2010-06-15 Process for production of heterodimers of glutamic acid

Publications (3)

Publication Number Publication Date
BR112012000209A2 true BR112012000209A2 (pt) 2017-07-11
BR112012000209B1 BR112012000209B1 (pt) 2020-10-13
BR112012000209B8 BR112012000209B8 (pt) 2021-07-27

Family

ID=43067201

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112012000209A BR112012000209B8 (pt) 2009-06-15 2010-06-15 heterodímeros de ácido glutâmico e seus processos de preparação
BR112012000210A BR112012000210A2 (pt) 2009-06-15 2010-06-15 processo para a produção de heterodímeoros de ácido glutâmico.

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112012000210A BR112012000210A2 (pt) 2009-06-15 2010-06-15 processo para a produção de heterodímeoros de ácido glutâmico.

Country Status (4)

Country Link
US (2) US8465725B2 (pt)
AU (1) AU2010260195B2 (pt)
BR (2) BR112012000209B8 (pt)
WO (1) WO2010147965A2 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6528499B1 (en) * 2000-04-27 2003-03-04 Georgetown University Ligands for metabotropic glutamate receptors and inhibitors of NAALADase
EP2097111B1 (en) 2006-11-08 2015-07-15 Molecular Insight Pharmaceuticals, Inc. Heterodimers of glutamic acid
PL2187965T3 (pl) 2007-08-17 2020-05-18 Purdue Research Foundation Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
EA201590783A1 (ru) 2012-11-15 2015-11-30 Эндосайт, Инк. Конъюгаты для доставки лекарственных средств и способы лечения заболеваний, вызванных клетками, экспрессирующими psma
US20150110814A1 (en) 2013-10-18 2015-04-23 Psma Development Company, Llc Combination therapies with psma ligand conjugates
EP3456700A1 (en) 2013-10-18 2019-03-20 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
JP6908964B2 (ja) 2013-10-18 2021-07-28 ピーエスエムエー ディベロップメント カンパニー,エルエルシー Psmaリガンドコンジュゲートによる併用療法
EP3533473A3 (en) 2013-11-14 2019-12-18 Endocyte, Inc. Compounds for positron emission tomography
US20150147339A1 (en) 2013-11-15 2015-05-28 Psma Development Company, Llc Biomarkers for psma targeted therapy for prostate cancer
JP2017530109A (ja) 2014-09-08 2017-10-12 モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド 前立腺癌についてのpsmaを標的とした放射性核種治療中の臓器の保護
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
CN112368024A (zh) 2018-04-17 2021-02-12 恩多塞特公司 治疗癌症的方法
CN114096264B (zh) 2019-05-20 2025-03-14 因多塞特股份有限公司 制备psma缀合物的方法
CN111072653A (zh) * 2019-12-26 2020-04-28 浙江工业大学 一种由取代2-芳基吲哚嗪直接合成1,3-双硫代吲哚嗪类化合物的方法
WO2021202376A1 (en) 2020-03-30 2021-10-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for blocking uptake of prostate-specific membrane antigen (psma)-targeted radionuclides by exocrine organs
WO2025250655A1 (en) * 2024-05-29 2025-12-04 Cornell University Preparation of radiohalogenated compounds for nuclear medicine by reductive elimination from bismuth(v) halides

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2730457A (en) 1953-06-30 1956-01-10 Ncr Co Pressure responsive record materials
US2800457A (en) 1953-06-30 1957-07-23 Ncr Co Oil-containing microscopic capsules and method of making them
US2730456A (en) 1953-06-30 1956-01-10 Ncr Co Manifold record material
US3527789A (en) 1967-10-06 1970-09-08 Shell Oil Co Production of poly(lower)alkyl alkenepolycarboxylates
US3625214A (en) 1970-05-18 1971-12-07 Alza Corp Drug-delivery device
US4272398A (en) 1978-08-17 1981-06-09 The United States Of America As Represented By The Secretary Of Agriculture Microencapsulation process
US4906474A (en) 1983-03-22 1990-03-06 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
JPS6131056A (ja) 1984-07-25 1986-02-13 K Baiorojikaru Sci Lab:Kk ホイッピングクリームの製造方法
AU610083B2 (en) 1986-08-18 1991-05-16 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents
JP2608550B2 (ja) 1986-10-17 1997-05-07 株式会社 片山化学工業研究所 軟水ボイラの防食処理方法
US4888136A (en) 1988-05-02 1989-12-19 Witco Corporation New flame retardant compositions of matter and cellulosic products containing same
TW353663B (en) 1991-04-06 1999-03-01 Hoechst Ag Process for the preparation of phosphorus-containing L-amino acids, their derivatives and intermediates for this process
JP3051497B2 (ja) 1991-05-17 2000-06-12 株式会社第一ラジオアイソトープ研究所 スルファニルアミド誘導体のテクネチウム錯体をもちいる放射性診断剤
NZ244613A (en) 1991-10-29 1996-05-28 Bracco International B V Subst A ligand containing a hypoxia-localising moiety, preparation thereof; a kit (optionally multivial) for preparing a metal complex containing the ligand
US6359120B1 (en) 1991-10-29 2002-03-19 Bracco International B.V. Rhenium and technetium complexes containing a hypoxia-localizing moiety
IT1270260B (it) 1994-06-21 1997-04-29 Zambon Spa Derivati dell'acido fosfonico ad attivita' inibitrice delle metallopeptidasi
US6011021A (en) 1996-06-17 2000-01-04 Guilford Pharmaceuticals Inc. Methods of cancer treatment using naaladase inhibitors
JP2856098B2 (ja) 1995-04-11 1999-02-10 日本製紙株式会社 感熱記録シート
US5795877A (en) 1996-12-31 1998-08-18 Guilford Pharmaceuticals Inc. Inhibitors of NAALADase enzyme activity
US5672592A (en) 1996-06-17 1997-09-30 Guilford Pharmaceuticals Inc. Certain phosphonomethyl-pentanedioic acid derivatives thereof
US6046180A (en) 1996-06-17 2000-04-04 Guilford Pharmaceuticals Inc. NAALADase inhibitors
US5902817A (en) 1997-04-09 1999-05-11 Guilford Pharmaceuticals Inc. Certain sulfoxide and sulfone derivatives
US5824662A (en) 1996-09-27 1998-10-20 Guilford Pharmaceuticals Inc. Treatment of global and focal ischemia using naaladase inhibitors
US6071965A (en) 1996-06-17 2000-06-06 Guilford Pharmaceuticals Inc. Phosphinic alkanoic acid derivatives
US6025344A (en) 1996-06-17 2000-02-15 Guilford Pharmaceuticals Inc. Certain dioic acid derivatives useful as NAALADase inhibitors
CA2264043A1 (en) 1996-09-27 1998-04-02 Guilford Pharmaceuticals Inc. Naaladase compositions and methods for treating glutamate abnormality and effecting neuronal activity in animals
US5962521A (en) 1997-04-04 1999-10-05 Guilford Pharmaceuticals Inc. Hydroxamic acid derivatives
ZA983930B (en) 1997-05-14 1999-11-08 Lilly Co Eli Excitatory amino acid receptor modulators.
CA2320167A1 (en) 1998-03-19 1999-09-23 Steven R. Turner 1,3,4-thiadiazoles useful for the treatment of cmv infections
AU773915B2 (en) 1999-04-28 2004-06-10 Georgetown University Ligands for metabotropic glutamate receptors
US6528499B1 (en) 2000-04-27 2003-03-04 Georgetown University Ligands for metabotropic glutamate receptors and inhibitors of NAALADase
US6228888B1 (en) 1999-07-01 2001-05-08 Guilford Pharmaceuticals Inc. Methods for treating anxiety, anxiety disorders and memory impairment using naaladase inhibitors
US20040157818A1 (en) 2001-05-24 2004-08-12 Mikiro Yanaka Cxcr4-antagonistic drugs composed of nitrogen-containing compound
DE10135355C1 (de) 2001-07-20 2003-04-17 Schering Ag Konjugate makrocyclischer Metallkomplexe mit Biomolekülen und deren Verwendung zur Herstellung von Mitteln für die NMR- und Radiodiagnostik sowie die Radiotherapie
US20030100594A1 (en) 2001-08-10 2003-05-29 Pharmacia Corporation Carbonic anhydrase inhibitor
DE10297577B4 (de) 2001-12-21 2007-11-22 Tohru Koike Zinkkomplexe, die fähig sind, Substanzen, die anionische Substituenten haben, abzufangen
WO2003060523A1 (en) 2002-01-10 2003-07-24 Johns Hopkins University Imaging agents and methods of imaging naaladase of psma
AU2003213819C1 (en) 2002-03-11 2010-03-04 Molecular Insight Pharmaceuticals, Inc. Technetium-dipyridine complexes, and methods of use thereof
AU2003261974A1 (en) 2002-09-11 2004-04-30 Kureha Chemical Industry Company, Limited Amine compounds and use thereof
US7550424B2 (en) 2002-11-26 2009-06-23 Institute Of Virology Slovak Academy Of Sciences CA IX-specific inhibitors
US7833734B2 (en) 2002-11-26 2010-11-16 Institute Of Virology Of The Slovak Academy Of Sciences CA IX-specific inhibitors
WO2004091518A2 (en) 2003-04-11 2004-10-28 Anormed Inc. Cxcr4 chemokine receptor binding compounds
US7682601B2 (en) 2003-04-15 2010-03-23 Mallinckrodt Inc. Bifunctional tridentate pyrazolyl containing ligands for re and tc tricarbonyl complexes
JP2007513928A (ja) 2003-12-12 2007-05-31 オサケユイチア ユバンティア ファーマ リミティド ソマトスタチン受容体サブタイプ1(sstr1)活性化合物及び治療におけるその使用
WO2005079865A1 (en) 2004-02-12 2005-09-01 Molecular Insight Pharmaceuticals Technetium- and rhenium-bis(heteroaryl) complexes, and methods of use thereof
GB0421308D0 (en) 2004-09-24 2004-10-27 Amersham Plc Enzyme inhibitor imaging agents
WO2008059489A2 (en) 2006-11-13 2008-05-22 Spectrum Dynamics Llc Radioimaging applications of and novel formulations of teboroxime
WO2006080993A1 (en) 2004-12-08 2006-08-03 Purdue Research Foundation Novel cationic metal complex radiopharmaceuticals
US20060155021A1 (en) 2005-01-13 2006-07-13 Lenges Christian P Coating compositions containing rheology control agents
US7741510B2 (en) 2005-01-13 2010-06-22 E. I. Du Pont De Nemours And Company Rheology control agents
WO2006093991A1 (en) 2005-03-02 2006-09-08 The Cleveland Clinic Foundation Compounds which bind psma and uses thereof
ATE527542T1 (de) 2005-04-27 2011-10-15 Siemens Medical Solutions Verfahren zur herstellung von abbildungssonden unter verwendung von click chemie
WO2007008848A2 (en) * 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
FR2890657B1 (fr) 2005-09-15 2007-11-09 Commissariat Energie Atomique Procede d'obtention de complexes de lanthanides hautement luminescents.
US8926945B2 (en) 2005-10-07 2015-01-06 Guerbet Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium
WO2007058322A1 (ja) 2005-11-18 2007-05-24 Ono Pharmaceutical Co., Ltd. 塩基性基を含有する化合物およびその用途
BRPI0621307A2 (pt) 2006-02-06 2011-12-06 Ciba Holding Inc. uso de compostos de complexo metálico como catalisadores de oxidação
WO2007132846A1 (ja) 2006-05-16 2007-11-22 Ono Pharmaceutical Co., Ltd. 保護されていてもよい酸性基を含有する化合物およびその用途
CN101472895A (zh) 2006-06-20 2009-07-01 石原产业株式会社 含有新的吡啶基-甲胺衍生物或其盐的有害生物防除剂
JP5245827B2 (ja) 2006-07-31 2013-07-24 小野薬品工業株式会社 スピロ結合した環状基を含有する化合物およびその用途
AU2007289168A1 (en) 2006-08-29 2008-03-06 Molecular Insight Pharmaceuticals, Inc. Radioimaging moieties coupled to peptidase-binding moieties for imaging tissues and organs that express peptidases
EP2097111B1 (en) 2006-11-08 2015-07-15 Molecular Insight Pharmaceuticals, Inc. Heterodimers of glutamic acid
KR20120003499A (ko) 2007-04-05 2012-01-10 지멘스 메디컬 솔루션즈 유에스에이, 인크. 클릭 화학을 이용한 탄산탈수효소―ⅰⅹ에 대한 분자 영상화 프로브의 제조
WO2009076434A1 (en) 2007-12-12 2009-06-18 Molecular Insight Pharmaceuticals, Inc. Inhibitors of integrin vla-4
RU2498798C2 (ru) 2008-01-09 2013-11-20 Моликьюлар Инсайт Фармасьютикалз, Инк. Ингибиторы карбоангидразы iх
US8562945B2 (en) 2008-01-09 2013-10-22 Molecular Insight Pharmaceuticals, Inc. Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof
WO2010036814A1 (en) 2008-09-25 2010-04-01 Molecular Insight Pharmaceuticals, Inc. Selective seprase inhibitors
JP2012511024A (ja) 2008-12-05 2012-05-17 モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド 癌の治療及び撮像用のca−ix特異性放射性医薬品
WO2010065906A2 (en) 2008-12-05 2010-06-10 Molecular Insight Pharmaceuticals, Inc. Ca-ix specific radiopharmaceuticals for the treatment and imaging of cancer

Also Published As

Publication number Publication date
US9149547B2 (en) 2015-10-06
BR112012000209B1 (pt) 2020-10-13
WO2010147965A3 (en) 2011-07-28
AU2010260195A1 (en) 2012-01-19
US20110008253A1 (en) 2011-01-13
WO2010147965A2 (en) 2010-12-23
BR112012000210A2 (pt) 2019-09-24
BR112012000209B8 (pt) 2021-07-27
US20140030188A1 (en) 2014-01-30
AU2010260195B2 (en) 2014-11-20
US8465725B2 (en) 2013-06-18

Similar Documents

Publication Publication Date Title
BR112012000209A2 (pt) processo para a produção de heterodímeros de ácido glutâmico
BRPI0910916A2 (pt) Processo para a produção de um dianidroaçúcar
BRPI1013296A2 (pt) processo para a produção de polidienos
BRPI1014812A2 (pt) Processo para a produção de alacoóis
BRPI0913622A2 (pt) Processo para a produção fermentativa de eritropoietina
BR112012003615A2 (pt) processo para a produção de butadieno
BRPI0917984A2 (pt) processo em batelada para a produção de poliamidas
BRPI1012370A2 (pt) processo para a produção de olefinas
PT2744768T (pt) Processo para a produção de clínquer de ternesite
PT2639222T (pt) Processo de produção de ácidos cicloalquilcarboxamido-piridina-benzoicos
BR112013002925A2 (pt) processo para a síntese de ácido 2,5-furandicarboxílico
BRPI1010759A2 (pt) processo para produção de proteína
BRPI0909368A2 (pt) processo contínuo para a fabricação de alcanolamidas de ácido graxo
BRPI0915572A2 (pt) processo para a fabricação de epicloroidrina
BR112012005418A2 (pt) processo para a produção de grânulos
BR112012014490A2 (pt) processo para a preparação substituída de 1-o-acil-2-desóxi-2-fluoro-4-tio-beta-d-arabinofuranoses
IT1395068B1 (it) Processo per la produzione di galatto-oligosaccaridi ultrapuri
BRPI0914788A2 (pt) Processo para a produção de um produto intermediário de etexilato de dabigatran
BR112012016247A2 (pt) processo contínuo para a produção de derivados de ácidos carboxílicos saturados
BRPI0908900A2 (pt) processo para a produção de polióis
BR112013008883A2 (pt) processo para a fabricação de di-hidropteridinonas
BRPI0909004A2 (pt) Processo para produção de biogás
BRPI0813960A2 (pt) Processo para produção de biarilas
BR112013009837A2 (pt) processo para a produção de ácido poliláctico usando monascus
BR112012001274A2 (pt) processo para produção de ácidos decancarboxílicos

Legal Events

Date Code Title Description
B15G Petition not considered as such [chapter 15.7 patent gazette]
B151 Others concerning applications: resolution cancelled [chapter 15.31 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 13/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/06/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO